| Volume 24, 2020 Articles |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
PreScription: One Size Does Not Fit All!
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 4
|
Primary Engineering Controls in Pharmaceutical Compounding, Part 2: Biosafety Cabinets
Mulder Kyle
|
Jan/Feb 2020
Pg. 7-12
|
How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems
Vaughn Stacey R, Radwick Allison
|
Jan/Feb 2020
Pg. 14-19
|
Performing a United States Pharmacopeia Chapter <800> Compliant Assessment of Risk
Cabaleiro Joe
|
Jan/Feb 2020
Pg. 21-27
|
New and Improved!
Brunner Scott
|
Jan/Feb 2020
Pg. 28-29
|
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
|
Jan/Feb 2020
Pg. 30-36
|
Basics: Excipients Used in Nonsterile Compounding, Part 4: Antioxidants and Chelating Agents
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 38-43
|
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 44-50
|
Calculations
Stockton Shelly J
|
Jan/Feb 2020
Pg. 52
|
Amiodarone Hydrochloride 5 mg/mL in SyrSpend SF pH4 Cherry Flavored
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 54
|
Glutamine 250 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 55
|
Glycopyrrolate 0.2 mg/mL in Methylcellulose 1% and Syrup
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 56
|
Hydrocortisone 2%, Iodoquinol 1% Metronidazole 10%, and Zinc Oxide 2% in Polyethylene Glycol Ointment
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 57
|
Isoniazid 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 58
|
LCD 5%, Salicylic Acid 6% in Clobetasol Propionate 0.05% Ointment
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 59
|
Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 60
|
Potassium Chloride 1 mmol/mL in Ora-Sweet SF
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 61
|
Progesterone 100-mg, Melatonin 1-mg, and L-Theanine 200-mg Slow-Release Capsules
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 62
|
Venlafaxine 15 mg/mL in Syrup
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 63
|
Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit
Lardinois Benjamin, Dimitriou Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence M
|
Jan/Feb 2020
Pg. 64-68
|
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution
Marotta James C, Patel Gopesh, Carvalho Maria, Blakeney Samantha
|
Jan/Feb 2020
Pg. 69-76
|
Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets
Jarouche Marian, Ibrahim Martha, Pearson Jarryd, Low Mitchell, Rowe James
|
Jan/Feb 2020
Pg. 77-82
|
Compatibility of Melphalan in Iodinated Contrast Media
Shi Zhanquan, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
|
Jan/Feb 2020
Pg. 83-85
|
Errata - How to Qualify Container Closure Systems for Intended Use, Part 1 - IJPC 23(6) 454-461
|
Jan/Feb 2020
Pg. 86-87
View Sample |
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 92
|
Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
|
Mar/Apr 2020
Pg. 94-96
|
Compounding Pearls -- Wound Care: Base Selection
Riepl Mike
|
Mar/Apr 2020
Pg. 98-102
|
Low-dose Pilocarpine Spray to Treat Xerostomia
Zur Eyal
|
Mar/Apr 2020
Pg. 104-108
|
A "North Star" for Pharmacy Compounders
Brunner Scott
|
Mar/Apr 2020
Pg. 110-113
|
Basics of Nonsterile Compounding: Excipients Used in Nonsterile Compounding, Part 5: Compounding Using Solvents and Cosolvent Systems
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 114-118
|
Intravenous Admixture Preparation Considerations, Part 3: Methods and Techniques to Decrease Incompatibilities
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 121-126
|
Calculations
Stockton Shelly J
|
Mar/Apr 2020
Pg. 128
|
Acetazolamide 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 130
|
Cholecalciferol 50,000 IU/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 131
|
Glycopyrrolate 0.2 mg/mL in Ora-Plus:Ora-Sweet (1:1)
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 132
|
Minocycline Hydrochloride 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 133
|
Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 134
|
Propylthiouracil 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 135
|
Quinidine Sulfate 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 136
|
Terbinafine 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 137
|
Topiramate 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 138
|
Valsartan 4 mg/mL in Syrup NF
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 139
|
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
|
Mar/Apr 2020
Pg. 140-147
|
Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets
Mahesparan Vishnu A/L, Bin Abd Razak Fashli Syafiq, Ming Long Chiau, Uddin ABM Helal, Sarker Md Zaidul Islam, Bin Liew Kai
|
Mar/Apr 2020
Pg. 148-155
|
Physicochemical Stability of Ternary Mixtures of Sufentanil, Baclofen, and Ropivacaine in Polypropylene Syringes for Intrathecal Analgesia
Sorrieul Jérémy, Robert Julien, Chapel Fanny, Gossye Thomas, Devys Catherine
|
Mar/Apr 2020
Pg. 156-162
|
Feasibility Study of Asthma Cream
Kuang Andrew
|
Mar/Apr 2020
Pg. 163-167
|
Percutaneous Absorption of Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol from ABH Gel
Dahal Amit, Neupane Rabin, Boddu Sai HS, Renukuntla Jwala, Khupse Rahul, Dudley Richard
|
Mar/Apr 2020
Pg. 168-175
|
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2
Allen Loyd V Jr
|
May/Jun 2020
Pg. 180
|
Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1
Riepl Mike
|
May/Jun 2020
Pg. 182-186
|
Compounding Pearls -- Wound Care: Burn Healing, Part 1
Riepl Mike
|
May/Jun 2020
Pg. 188-193
|
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III, Everett Eric, Chamberlain Tyler
|
May/Jun 2020
Pg. 194-197
|
U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk
Brunner Scott
|
May/Jun 2020
Pg. 198-199
|
Quality Control: Photostability of Compounded Preparations
Allen Loyd V Jr
|
May/Jun 2020
Pg. 200-205
|
Basics: Excipients Used in Nonsterile Compounding, Part 6: Compounding with Viscosity-increasing Agents
Allen Loyd V Jr
|
May/Jun 2020
Pg. 206-212
|
Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates
Allen Loyd V Jr
|
May/Jun 2020
Pg. 215-220
|
Calculations
Stockton Shelly J
|
May/Jun 2020
Pg. 222
|
Baclofen 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2020
Pg. 224
|
Dexamethasone 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2020
Pg. 225
|
Diphenylcyclopropenone 0.1% or 3% in Isopropranol
Allen Loyd V Jr
|
May/Jun 2020
Pg. 226
|
Ibuprofen 400-mg and Cyclobenzaprine 2.5-mg Capsules
Allen Loyd V Jr
|
May/Jun 2020
Pg. 227
|
Monsel's Solution, Gel, and Paste
Allen Loyd V Jr
|
May/Jun 2020
Pg. 228
|
Prednisolone 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2020
Pg. 229
|
Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension
Allen Loyd V Jr
|
May/Jun 2020
Pg. 230
|
Tetracycline Hydrochloride 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2020
Pg. 231
|
Ursodiol 100 mg/mL in Cod Liver Oil, Veterinary
Allen Loyd V Jr
|
May/Jun 2020
Pg. 232
|
Venlafaxine 15 mg/mL in Ora-Plus:Ora-Sweet (1:1) Suspension
Allen Loyd V Jr
|
May/Jun 2020
Pg. 233
|
Comparative Stability Study of Unit-dose Vancomycin Hydrochloride Oral Solutions in Plastic Capped Oral Syringes and Plastic Sealed Dosage Cups
Brown Stacy, Lewis Paul
|
May/Jun 2020
Pg. 234-237
|
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Wilder Alyson G, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
|
May/Jun 2020
Pg. 238-241
|
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley, Patel Jalpa
|
May/Jun 2020
Pg. 242-245
|
Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
|
May/Jun 2020
Pg. 246-251
|
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
|
May/Jun 2020
Pg. 252-262
|
PreScription: COVID-19 and Compounding Pharmacists
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 268
|
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Greeson Nicole MH, Mixon William, Allan W Chris
|
Jul/Aug 2020
Pg. 270-276
|
Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 2
Riepl Mike
|
Jul/Aug 2020
Pg. 278-281
|
Compounding Pearls -- Wound Care: Burn Healing, Part 2
Riepl Mike
|
Jul/Aug 2020
Pg. 282-285
|
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
McElhiney Linda F
|
Jul/Aug 2020
Pg. 287-295
|
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
|
Jul/Aug 2020
Pg. 296-297
|
Quality Control: Rapid Sterility Testing for Compounding Pharmacies
Taylor Andrew
|
Jul/Aug 2020
Pg. 299-303
|
Sterile Basics: Intravenous Admixture Preparation Considerations, Part 5: pH Considerations
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 305-309
|
Calculations
Stockton Shelly J
|
Jul/Aug 2020
Pg. 310
|
Benzonatate 50 mg/mL in Ora-Sweet
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 312
|
Cyclobenzaprine 5-mg/g and Guaifenesin 10-mg/g Transdermal Cream
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 313
|
Doxepin Hydrochloride 5% in Cetaphil Cream
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 314
|
Hydrocortisone Hemisuccinate 2 mg/mL or Hydrocortisone Sodium Phosphate 2 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 315
|
Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 316
|
Hydroxyzine (Pamoate) 25-mg/mL Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 317
|
Lisinopril 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 318
|
Lorazepam 1 mg/mL in a Nonaqueous Cosolvent Vehicle
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 319
|
Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream)
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 320
|
Tramadol Hydrochloride 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 321
|
Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal, Levesque Dan, Frye John, Rashid Mamoon
|
Jul/Aug 2020
Pg. 322-326
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Song Guiyun, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
|
Jul/Aug 2020
Pg. 337-345
|
Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review
Milibari Loay, Cotugno Michael, Belisle Caryn, Rocchio Megan, Patterson Robert F, Chacon Pablo, Fanikos John, Vo Peter
|
Jul/Aug 2020
Pg. 346-351
|
Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 356
|
Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients
Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
|
Sep/Oct 2020
Pg. 358-364
|
Topical Cholesterol/Simvastatin Gel for the Treatment of CHILD Syndrome in an Adolescent
Cho Sung Kyung, Ashworth Lisa Diggs, Goldman Shauna
|
Sep/Oct 2020
Pg. 367-369
|
Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Greeson Nicole MH, Mixon William, Allan W Chris
|
Sep/Oct 2020
Pg. 371-379
|
Houston, We Have a Study': History-making African Research Relies on a Maverick Texas Pharmaceutical Compounder
Lovell Nancy
|
Sep/Oct 2020
Pg. 380-385
|
An Unconscionable, Unnecessary Fight
Brunner Scott
|
Sep/Oct 2020
Pg. 386-387
|
Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 7: Compounding with Surfactants
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 388-395
|
Intravenous Admixture Preparation Considerations, Part 6: pH Considerations -- Applications
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 397-402
|
Calculations
Stockton Shelly J, Bui Phi H
|
Sep/Oct 2020
Pg. 404
|
Ketamine 60.6-mg/mL, Acepromazine 0.6-mg/mL, and Xylazine 6.67-mg/mL Injection
(Vet-Rat and Hamster); Ketamine 6.06-mg/mL, Acepromazine 0.06-mg/mL, and Xylazine 0.667-mg/mL Injection
(Vet-Mouse)
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 406
|
Levofloxacin 50 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 407
|
Always the Right Dose? Content Uniformity in Over 100 Different Formulations Tested
Dijkers Eli, Polonini Hudson, de Oliveira Ferreira Anderson
|
Sep/Oct 2020
Pg. 408-412
|
Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
|
Sep/Oct 2020
Pg. 413-419
|
Biotin Regulates Colonization and Growth of Candida albicans in the Catheter Lumen During Nutrient Infusions
Ohara Hiroshi, Matsuzaki Tetsuya, Ochiai Tatsuya, Hayasaka Masataka
|
Sep/Oct 2020
Pg. 420-425
|
Efficacy of an Automated Robotic Cleaning Device for Compounding Pharmacies
Polonini Hudson, Dijkers Eli CF, Ferreira Anderson O, da Silva Sharlene L, Araújo Paulo Victor C, Koulouridas Savvas
|
Sep/Oct 2020
Pg. 426-433
|
Evaluation of the Efficacy and Superiority of Different Vial Rubber Closure Disinfection Techniques
Bjornstad Matthew, Kosinski Tracy, Burlage Robert
|
Sep/Oct 2020
Pg. 434-438
|
PreScription: The NASEM cBHT Report, Part 1
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 444
|
NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 446-448
|
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris, Greeson Nicole MH, Mixon William
|
Nov/Dec 2020
Pg. 451-458
|
Establishing a Structured Pharmacy Training Program in Sterile Compounding
Dirbas Muhannad, AbuSara Aseel K, Whiyabi Shatha, Harb Rema, Telfah Shorouq
|
Nov/Dec 2020
Pg. 460-465
|
Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1
DeRosa Angela
|
Nov/Dec 2020
Pg. 466-470
|
Intravenous Admixture Preparation Considerations, Part 7: Stability Issues
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 473-478
|
Calculations
Drinnon Stephen D, Stockton Shelly J
|
Nov/Dec 2020
Pg. 480
|
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Nov/Dec 2020
Pg. 482-490
|
Analysis of Extemporaneously Compounded Nasal Preparations Prescribed by Latvian Otorhinolaryngologists and General Practitioners and Comparison with German Formulations
Kiselova Olga, Maurina Baiba, Sidlovska Venta
|
Nov/Dec 2020
Pg. 491-500
|
Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Nov/Dec 2020
Pg. 501-508
|
Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract
Azman Syahiera Ezzah Noor, Abd Razak Fashli Syafiq, Kamal Wan Hamirul Bahrin Wan, Zheng Gan Kok, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
|
Nov/Dec 2020
Pg. 509-514
|
Development and Evaluation of an Anti-aging Cosmetic Formulation Exploring Antioxidant Potential of Vitis vinifera L.
Carneiro Jaqueline, Marques Gonçalves Melissa, Vicente Pereira Airton
|
Nov/Dec 2020
Pg. 515-518
|
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure
Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott
|
Nov/Dec 2020
Pg. 519-527
|
Erratum: IJPC. 2020; 24(4):
327 Stability of Extemporaneous Oral Tramadol, Fluoxetine, and
Doxycycline Suspensions in SyrSpend SF PH4
|
Nov/Dec 2020
Pg. 527
View Sample |
| Return to Top |
